Centre National De La Recherche Scientifique

Institut Gustave Roussy

Université Paris Sud Xi

Merial Limited

Viroxis Sas

Université Paris—sud

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Université Paris-saclay

Inserm (institut National De La Sante Et De La Recherche Medicale)

Université De Paris-sud Xi

Thierry Heidmann

Herve Poulet

Martial Renard

Vladimir Lazar

Marianne Mangeney

Hervé Poulet

Jean-Francedillaois Nicolas

Marie Dewannieux

Sandra Blaise

Laurence Benit

Nathalie De Parseval

A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

Mutated non-primate lentiviral Env proteins and their use as drugs

The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.

Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene

A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties

Described is the use of a mutation of at least one amino acid in the immunosuppressive domain of a HIV or SIV accessory protein, for modulating the immunosuppressive property of the protein.

Mutated HIV Nef for modulating immunity

Mutated viral ENV proteins having mutations in the immunosuppressive domain (ISU) of the transmembrane subunit (TM) have decreased immunosuppressive activity with respect to the wild-type ENV protein. Pharmaceutical compositions that include the protein and nucleic acids coding for the protein are also disclosed.

Mutated env sequence involved in the modulation of the immunosuppressive effect of viral proteins

The present invention relates to a polypeptide having a sequence of 7 to 20 amino acid residues, which is capable of modulating the immunosuppressive properties of a viral protein or a fragment thereof, against the host in which it is expressed (immunosuppression-modulatory sequence) when it substitutes the homologous sequence of the viral protein or fragment, the polypeptide including the minimum following consensus amino acid sequence:XYYYCYXwherein, Xand Xare selected to impact on the immunosuppressive properties, and Yto Yrepresent variable amino acid residues.

Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins

The invention relates to a defective recombinant retrovirus containing a sequence coding for a specific protein in the genome of the cells. The DNA of the recombinant retrovirus contains the sequence coding for the protein intercalated between an acceptor splicing site and a donor splicing site, the whole assembly being placed under the control of a suitable promoter under conditions such that the infection of the said cells by this recombinant retrovirus is accompanied by the incorporation of the sequence coding for the protein into the genome of the infected cells.

Defective recombinant retrovirus

Growing community of inventors

Paris, France

Thierry Heidmann